Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) Debt to Equity: 2020-2022

  • Mereo BioPharma Group's Debt to Equity fell 99.16% to $0.01 in Q4 2022 from the same period last year, while for Dec 2022 it was $0.01, marking a year-over-year decrease of 99.16%. This contributed to the annual value of $0.01 for FY2022, which is 99.16% down from last year.
  • According to the latest figures from Q4 2022, Mereo BioPharma Group's Debt to Equity is $0.01, which was up 1,140.72% from $0.00 recorded in Q2 2022.
  • In the past 5 years, Mereo BioPharma Group's Debt to Equity ranged from a high of $1.59 in Q2 2021 and a low of -$0.10 during Q4 2020.
  • In the last 3 years, Mereo BioPharma Group's Debt to Equity had a median value of $0.06 in 2020 and averaged $0.46.
  • Per our database at Business Quant, Mereo BioPharma Group's Debt to Equity skyrocketed by 1,252.14% in 2021 and then tumbled by 99.95% in 2022.
  • Over the past 3 years, Mereo BioPharma Group's Debt to Equity (Quarterly) stood at -$0.10 in 2020, then surged by 1,216.91% to $1.13 in 2021, then crashed by 99.16% to $0.01 in 2022.
  • Its Debt to Equity stands at $0.01 for Q4 2022, versus $0.00 for Q2 2022 and $1.13 for Q4 2021.